Positive Phase 2 Clinical Trial Results Of Piromelatine For Treatment Of Insomnia
Monday, February 18, 2013 - 12:10
in Health & Medicine
Neurim Pharmaceuticals has announced positive results from a phase II clinical study evaluating the efficacy and safety of Piromelatine (Neu-P11), a novel investigational multimodal sleep medicine developed for the treatment of patients with primary and co-morbid insomnia. The new results are from a recent double-blind, randomized, placebo controlled, parallel group, non-confirmatory, sleep-laboratory study. The study evaluated piromelatine compared to placebo in 120 adult primary insomnia patients, ages 18 years and older. read more